Drugs / FIANLIMAB DFO ZR-89
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04566978 | Sep 2020 → Mar 2025 | diffuse large B-cell lymphoma, large B-cell lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04706715 | Jan 2022 → Nov 2025 overdue | metastatic neoplasm | University Medical Center Groningen | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FIANLIMAB DFO ZR-89 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068596 ↗ |
| Known as | 89Zr-DFO-REGN3767 | “ImmunoPET Imaging With 89Zr-DFO-REGN3767 in Patients With Advanced Solid Cancer Prior to and During Treatment With Cemiplimab With or Without Platinum-based Chemotherapy” NCT04706715 ↗ |
| Modality | Monoclonal antibody | “REGN3767 is an investigational monoclonal antibody” NCT04566978 ↗ |